Diffuse large B-cell lymphoma (DLBCL) was considered an incurable disease until the introduction of polychemotherapy (e.g., CHOP) in the 1970s. Treatment improved significantly with the introduction of the anti-CD20 antibody, rituximab, in combination with CHOP (R-CHOP), however, one-third of patients are either refractory to this initial treatment or relapse after treatment. Prof Laurie Sehn chaired a symposium as part of the 15th International Congress on Malignant Lymphoma (ICML) in Lugano, Switzerland, discussing the unmet need of DLBCL patients and the future of using antibody therapy.
Latest articles
All articles
9 Mins
14th
August
Recent Advancements in wAIHA
AIHA is an acquired, heterogeneous group of rare diseases with a prevalence of 17 per 100,000.1 This group includes wAIHA…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
3 Mins
25th
July
Filgrastim Prophylaxis for Neutropenia in Myelodysplasia Pre-Surgery: Case Report
Myelodysplastic syndromes are a group of disorders that affect the bone marrow, subsequently affecting the growth and relative…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.